跳至主要内容
临床试验/NCT00971633
NCT00971633已完成1 期

An Open-Label, Randomized, Single Dose, 3-period Crossover Study to Determine the Bioequivalence of 3 Formulations of Ondansetron in Healthy Young Adult Male and Female Subjects

Merck Sharp & Dohme LLC0 个研究点目标入组 12 人开始时间: 2003年11月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
主要终点
Maximum Plasma Concentration (Cmax) of Ondansetron

研究概览

简要总结

This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • If female, subject is not pregnant or breast-feeding
  • Subject is a nonsmoker
  • Subject is in good general health

排除标准

  • Subject has a history of high blood pressure, asthma, or cardiovascular, liver, neurologic, or kidney disease
  • Subject is taking prescription or nonprescription drugs that can not be discontinued during the study
  • Subject is a habitual and heavy consumer of caffeine

结局指标

主要结局

Maximum Plasma Concentration (Cmax) of Ondansetron

时间窗: 24 hours post dose

Area Under the Plasma Concentration-Time Curve From Zero to Infinity (AUC) of Ondansetron

时间窗: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 18, and 24 hours post dose

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验